Cephalon reaches $1 billion milestone in annual revenue

02/17/2005 | Philadelphia Inquirer, The

Cephalon's announcement puts it in a league with only eight other U.S. biotechnology companies, and the firm's CEO said he expects revenues to double to $2 billion by the end of 2008. In the coming two years, Cephalon faces a loss of patent for two of its biggest products, Provigil and Actiq, and one analyst said the company would need to "ramp up sales in the attention-deficit market" and get approval of another drug now in Phase III clinical trials to offset the expected generic competition for Provigil and Actiq.

View Full Article in:

Philadelphia Inquirer, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN